Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-694-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date2/21/2019 (Estimated)
OptionableOptionable
Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions
What is Arcus Biosciences' stock symbol?
Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences Inc (NYSE:RCUS) posted its quarterly earnings data on Thursday, November, 8th. The company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.13. The business earned $4.29 million during the quarter, compared to the consensus estimate of $1.40 million. View Arcus Biosciences' Earnings History.
When is Arcus Biosciences' next earnings date?
What price target have analysts set for RCUS?
4 analysts have issued 1-year price targets for Arcus Biosciences' stock. Their forecasts range from $18.00 to $22.00. On average, they expect Arcus Biosciences' stock price to reach $19.75 in the next year. This suggests a possible upside of 64.7% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.
What is the consensus analysts' recommendation for Arcus Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.
Has Arcus Biosciences been receiving favorable news coverage?
News headlines about RCUS stock have trended positive on Thursday, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arcus Biosciences earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include Endocyte (ECYT), Enanta Pharmaceuticals (ENTA), Supernus Pharmaceuticals (SUPN), Insmed (INSM), Xencor (XNCR), The Medicines (MDCO), PTC Therapeutics (PTCT), Biohaven Pharmaceutical (BHVN), Mallinckrodt (MNK), AnaptysBio (ANAB), Myokardia (MYOK), Arrowhead Pharmaceuticals (ARWR), Pacira Pharmaceuticals (PCRX), Opko Health (OPK) and Zai Lab (ZLAB).
What other stocks do shareholders of Arcus Biosciences own?
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the folowing people:
- Dr. Terry Rosen Ph.D., Co-Founder, CEO & Director (Age 59)
- Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
- Mr. Steven Chan, Principal Financial Officer (Age 47)
- Dr. Stephen Young Ph.D., VP of Technology (Age 50)
- Dr. Jay P. Powers, Sr. VP of Drug Discovery (Age 53)
When did Arcus Biosciences IPO?
(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.
Who are Arcus Biosciences' major shareholders?
Arcus Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Svennilson Peter (7.97%), Foresite Capital Management III LLC (4.56%), BlackRock Inc. (3.87%), Aisling Capital Management LP (1.21%), Hillhouse Capital Advisors Ltd. (0.96%) and Hillhouse Capital Management Ltd. (0.77%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.
Which major investors are selling Arcus Biosciences stock?
RCUS stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Partner Fund Management L.P., Hillhouse Capital Management Ltd., TD Asset Management Inc. and MML Investors Services LLC. View Insider Buying and Selling for Arcus Biosciences.
Which major investors are buying Arcus Biosciences stock?
RCUS stock was purchased by a variety of institutional investors in the last quarter, including Svennilson Peter, BlackRock Inc., Aisling Capital Management LP, Hillhouse Capital Advisors Ltd., Northern Trust Corp, Geode Capital Management LLC, Bank of New York Mellon Corp and Rhumbline Advisers. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.
How do I buy shares of Arcus Biosciences?
Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcus Biosciences' stock price today?
One share of RCUS stock can currently be purchased for approximately $11.99.
How big of a company is Arcus Biosciences?
Arcus Biosciences has a market capitalization of $532.96 million.
What is Arcus Biosciences' official website?
How can I contact Arcus Biosciences?
Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]
MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
